Valion Bio, Inc. filed 4 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-23. Between them they name 6 people, with 5 appointments and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Dean Zikria, Chief Executive Officer
On September 22, 2026, Valion Bio, Inc. (the "Company"), a Delaware corporation, appointed Dean Zikria as Interim Chief Executive Officer of the Company, effective immediately.
Departing: Sheryle Bolton
Board Resignation On September 17, 2026, Sheryle Bolton notified the Company of her decision to resign from the Company's Board, effective immediately.
Appointed: Jared Malbin, Director
On August 27, 2026, the Company appointed Jared Malbin as a member of the board of directors (the "Board"), effective immediately.
Appointed: Thomas Jensen, Director
On August 27, 2026, the Company appointed Thomas Jensen as a member of the Board, effective immediately.
Appointed: Lisa Wolf, Chief Operating Officer
On August 16, 2026, Valion Bio, Inc. (the "Company"), a Delaware corporation, appointed Lisa Wolf as Chief Operating Officer of the Company, effective immediately.
Appointed: Melinda Lackey, General Counsel
On May 4, 2026, Melinda Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs of Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.), a Delaware corporation (the "Company").
Valion Bio, Inc.'s funding history
Find people with the same kind of experience as the Chief Executive Officer at Valion Bio, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Valion Bio, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Valion Bio, Inc. is in the news or changes leadership.
Get an alert when Valion Bio, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Valion Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.